ReviewJACC. Advances2024
Atrial Fibrillation in Hypertrophic Cardiomyopathy.
Review in JACC. Advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impact of diabetes on outcomes in hypertrophic cardiomyopathy: a GRADE meta-analysis.Heart (British Cardiac Society) · 2026Pooled it
- Mechanistic diversity within RLC-dependent myosin ATPase inhibitors differentiates EDG-7500, a diastolic-selective cardiac sarcomere modulator.JCI insight · 2026Article
- Antiarrhythmic Drug Therapy in Cardiomyopathies: A Comparative Synthesis of Guidelines and Consensus Documents.Current cardiology reports · 2026Review
- Electrophysiological Substrate and Ablation Outcomes in Atrial Fibrillation With Hypertrophic Cardiomyopathy: A Propensity-Matched Multicenter Study.Journal of arrhythmia · 2026Article
- Cardiogenic shock and atrial fibrillation after mavacamten dose escalation in obstructive hypertrophic cardiomyopathy: a case report.European heart journal. Case reports · 2026Article
- Role of imaging techniques in monitoring atrial cardiomyopathy and atrial failure: a scientific statement.ESC heart failure · 2026Review
- Incremental Value of NT-proBNP Over HCM-AF Score in Risk Stratification for Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy.Clinical cardiology · 2026Article
- Additional Stroke Risk Factors Beyond the CHAJournal of clinical medicine · 2026Article
- Left Atrial Appendage Thrombus in Hypertrophic Cardiomyopathy With Atrial Fibrillation-Common and Resistant to Treatment.Journal of the American Heart Association · 2026Article
- Functional Validation of a Novel HomozygousHuman mutation · 2026Article
- Shared genetic architecture of HCM and AF: Elevated NPPA/ANP is linked to atrial electrical remodeling.PloS one · 2026Article
- Cellular and Molecular Mechanisms of Heart Failure and Sudden Cardiac Death in Hypertrophic Cardiomyopathy and Methods Used for Their Pathogenetic Correction.Biomedicines · 2025Review
- Characteristics and Outcomes of Mavacamten Use in 2440 Patients With Obstructive Hypertrophic Cardiomyopathy.Journal of the American Heart Association · 2025Observational
- Beyond the Left Atrium: Genetic and Renal Determinants of Atrial Fibrillation in Hypertrophic Cardiomyopathy.Korean circulation journal · 2025Article
- Cardiovascular comorbidities in hospitalized patients with hypertrophic cardiomyopathy and factors associated with a higher case-fatality rate.Future cardiology · 2025Article
- ECG markers of left ventricular hypertrophy indicate response to mavacamten in hypertrophic obstructive cardiomyopathy.Open heart · 2025Article
- Hypertrophic Cardiomyopathy: Current Perspectives.Reviews in cardiovascular medicine · 2025Review
- Advanced Diagnosis of Hypertrophic Cardiomyopathy with AI-ECG and Differences Based on Ethnicity and HCM Subtype.Journal of clinical medicine · 2025Article
- Correlation between left ventricular hypertrophy, myocardial fibrosis, and left atrial function in non-obstructive hypertrophic cardiomyopathy: insights from CMR-FT imaging.The international journal of cardiovascular imaging · 2025Article
- Temporal Patterns of Holter-Detected Arrhythmias in Hypertrophic Cardiomyopathy Patients Treated with Mavacamten.Biomedicines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrillation (AF) is common among patients with hypertrophic cardiomyopathy (HCM) with a prevalence greater than 25%. AF in HCM is associated with a high risk of stroke and can be a marker of more advanced cardiomyopathy. Although, it frequently results in cardiac hemodynamic changes which are poorly tolerated, it can be subclinical. Thus, prompt diagnosis and adequate management of AF are essential to minimizing AF-related adverse outcomes in HCM. All HCM patients should be screened for AF regularly, and those with high-risk features should be screened more frequently preferably with extended ambulatory monitoring. Once AF is detected, oral anticoagulation should be initiated. Both general and HCM-specific modifiable risk factors should be addressed and assessment for cardiomyopathy progression should be performed. Although no randomized controlled studies have compared rate versus rhythm control in HCM, early rhythm control could be considered to prevent further LA remodeling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.